Clinical pharmacology of dopamine agonists in Parkinson's disease

Drugs and Aging

Volumn 13, Issue 5, 1998, Pages 381-389

  Lange, Klaus W ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

DISEASE COURSE; DISEASE SEVERITY; DOPAMINE METABOLISM; DRUG EFFICACY; HUMAN; OXIDATIVE STRESS; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPTOM;

EID: 0031757441     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813050-00004     Document Type: Review

References (83)

1. Birkmayer W, Riederer P. Parkinson's disease. New York: Springer, 1983
2. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4
3. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292-6
4. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29: 1253-60
5. Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect 1991; 3: 151-201
6. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993; 329: 1021-7
7. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979; 277: 93-6
8. Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1994; 8: 263-70
9. 3H spiroperidol binding sites in rat striatum: evidence for actions of dopamine receptors not linked to adenylate cyclase. Life Sci 1978; 23: 465-70
10. Markstein R. Neurochemical effects of some ergot derivatives: a basis for their antiparkinsonian actions. J Neural Transm 1981; 51: 39-59
11. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990; 40 Suppl. 1: 50-4
12. Robertson GS, Robertson HA. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats. Brain Res 1986; 384: 387-90
13. Löschmann P-A, Smith LA, Lange KW, et al. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 1992; 109: 49-56
14. Grondin R, Bedard PJ, Britton DR, et al. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 1997; 49: 421-6
15. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a three-year follow-up. J Neurol Neurosurg Psychiatry 1989; 52: 773-5
16. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989; 39: 336-9
17. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990; 53: 224-6
18. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Which risk factors predict the levodopa response in fluctuating Parkinson's disease. Ann Neurol 1990; 27: 537-43
19. Roos RAC, Vredevoogd CB, Vandervelde EA. Response fluctuations in Parkinson's disease. Neurology 1990; 40: 1344-6
20. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993; 43: 21-7
21. Jankovic J. Long-term use of dopamine agonists in Parkinson's disease. Clin Neuropharmacol 1985; 8: 131-40
22. Riopelle RJ. Bromocriptine and the clinical spectrum of Parkinson's disease. Can J Neurol Sci 1987; 14: 455-9
23. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981; 44: 1020-3
24. Grimes JD, Delgado MR. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease. Clin Neuropharmacol 1985; 8: 73-7
25. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985; 35: 1196-8
26. Quinn N, Illas A, Lhermitte F, et al. Bromocriptine and domperidone in the treatment of Parkinson's disease. Neurology 1981; 31: 662-7
27. Lieberman AN, Goldstein M, Leibowitz M, et al. Long-term treatment with pergolide: decreased efficacy with time. Neurology 1984; 34: 223-6
28. Goetz CG, Tanner CM, Glantz RH, et al. Chronic agonist therapy for Parkinson's disease: a five-year study of bromocriptine and pergolide. Neurology 1985; 35: 749-51
29. Goetz CG, Shannon KM, Tanner CM, et al. Agonist substitution in advanced Parkinson's disease. Neurology 1989; 39: 1121-2
30. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988; 51: 529-33
31. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1009-14
32. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984; 107: 487-506
33. Sage JI, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988; 24: 87-9
34. Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations. Lancet 1986; 1: 467-70
35. Stibe CMH, Lees AJ, Stern GM. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations [letter]. Lancet 1987; 1: 871
36. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96-101
37. Coleman RJ, Lange KW, Quinn NP, et al. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Mov Disord 1990; 4: 129-38
38. Lange KW, Youdim MBH, Riederer P. Neurotoxicity and neuroprotection in Parkinson's disease. J Neural Transm 1992; Suppl. 38: 27-44
39. Sofie E, Lange KW, Jellinger K, et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992; 142: 128-30
40. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989; 53: 692-7
41. Lange KW, Löschmann P-A, Sofic E, et al. The competitive NMDA antagonist CPP protects substantia nigra neurones from MPTP-induced degeneration in primates. Naunyn-Schmiedebergs Arch Pharmacol 1993; 348: 586-92
42. Lange KW, Riederer P. Glutamatergic drugs in Parkinson's disease. Life Sci 1994; 54: 2067-75
43. Lange KW, Rausch W-D, Gsell W, et al. Neuroprotection by dopamine agonists. J Neural Transm 1994; Suppl. 43: 183-201
44. Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 1997; 21: 393-400
45. Felten DF, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats. Neurobiol Aging 1992; 13: 339-51
46. Clow A, Hussain T, Glover V, et al. Pergolide can induce soluble superoxide dismutase in rat striata. J Neural Transm Gen Sect 1992; 90: 27-31
47. Ubeda A, Montesinos C, Paya M, et al. Iron-reducing and free-radical scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic Biol Med 1993; 15: 159-67
48. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994; 62: 1034-8
49. Runge I, Horowski R. Can we differentiate symptomatic and neuroprotective effects in Parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl. J Neural Transm Park Dis Dem Sect 1991; 4: 273-83
50. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-7
51. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-7
52. Lichter D, Kurlan R, Miller C, et al. Does pergolide slow the progression of Parkinson's disease? A 7-year follow-up study [abstract]. Neurology 1988; 38 Suppl. 1: 122
53. Zimmerman T, Sage JI. Comparison of combination pergolide and levodopa to levodopa alone after 63 months of treatment. Clin Neuropharmacol 1941; 14: 165-9
54. Lieberman AN, Neophytides AV, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 1983; 37: 95-108
55. Mannen T, Mizuno Y, Iwata M, et al. A multi-center, double-blind study on slow-release bromocriptine in the treatment of Parkinson's disease. Neurology 1991; 41: 1598-602
56. Horowski R, Wachtel H. Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 1976; 36: 373-83
57. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993; 60: 653-5
58. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain 1991; 114: 601-14
59. Neumeyer JL, Samarthji L, Balderassini RJ. Historical highlights of the chemistry, pharmacology and early clinical uses of apomorphine. In: Gesse GL, Corsini GU, editors. Apomorphine and other dopaminomimetics. Vol. 1. Pharmacology. New York: Raven Press, 1981
60. Stibe CM, Kempster PA, Lees AJ, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; I: 403-6
61. Yahr MD, Clough CC, Bergmann KJ. Cholinergic and dopaminergic mechanisms in Parkinson's disease after king-term levodopa administration. Lancet 1982; II: 709-10
62. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995; 10: 37-43
63. Kapoor R, Turjanski N, Krankel J, et al. Intranasal apomorphine: a new treatment in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1990; 53: 1015
64. Lees AJ, Montastruc JL, Turjanski N, et al. Sublingual apomorphine and Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1989; 52: 1440
65. Hughes AJ, Bishop S, Lees AJ, et al. Rectal apomorphine in Parkinson's disease [letter]. Lancet 1991; 337: 118
66. Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991; 6: 212-6
67. Dewey Jr RB, Maraganore DM, Ahlskog JE, et al. Intranasal apomorphine rescue therapy for parkinsonian 'off' periods. Clin Neuropharmacol 1996; 19: 193-201
68. Van Laar T, Neef C, Danhof M, et al. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. Mov Disord 1996; 11: 633-8
69. Lera G, Vaamonde J, Muruzabal J, et al. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990; 28: 593-4
70. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine agonist, in Parkinson's disease patients with fluctuating responses to levodopa/ carhidopa. Neurology 1993; 43: 1981-4
71. Hutton JT, Morris JL, Brewer MA, et al. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993; 43: 613-6
72. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996; 46: 1062-5
73. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993; 43: 2587-90
74. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-47
75. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-45
76. Wachtel H, Dorow R. Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergol dopamine agonist lisuride. Life Sci 1983; 32: 421-32
77. Lange KW, Löschmann P-A, Wachtel H, et al. Terguride stimultes locomotor activity at 2 months but not 10 months following MPTP treatment of common marmosets. Eur J Pharmacol 1992; 212: 247-52
78. Corsini GU, Bonuccelli U, Rainer E, et al. Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. J Neural Transm 1985; 64: 105-11
79. Brocke T, Danielczyk W, Simányi M, et al. Terguride: partial dopamine agonist in the treatment of Parkinson's disease. Adv Neurol 1986; 45: 573-6
80. Critchley P, Parkes D. Transdihydrolisuride in parkinsonism. Clin Neuropharmacol 1987; 10: 57-64
81. Baronti F, Mouradian MM, Conant KE, et al. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 1992; 42: 1241-3
82. Ruggieri S, Stocchi F, Baronti F, et al. Antagonist effect of terguride in Parkinson's disease. Clin Neuropharmacol 1991; 14: 450-6
83. Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson's disease. Mov Disord 1998; 13: 249-54